Developments abound this week as our steadfast community continues to push for the advancement of important PBM reform policies to protect Americans on Medicare and Medicaid and the pharmacies that serve them. Beyond three PBM reform bills being advanced out of committee this week, we have learned another bill could be voted on by the ENTIRE U.S. House as early as Monday, December 11.
Yesterday, the bipartisan membership of the House Energy and Commerce Committee approved three pieces of legislation including important PBM reforms: (1) H.R. 5393 to require CMS to establish pharmacy quality measures in Part D and that includes important PBM transparency provisions; (2) H.R. 5385 to create reporting requirements for PBMs under Medicare Part D; and (3) H.R. 2880 to prohibit PBMs participating in Medicare Part D from linking their service fees to a drug's list price.
EVEN FURTHER, we have learned a full U.S. House vote on an amended Lower Cost, More Transparency Act (H.R. 5378) could take place as soon as MONDAY! The bill is a conglomeration of important House Energy and Commerce Committee and House Ways and Means Committee PBM reform provisions, including the broader PATIENT Act that advanced through the Energy & Commerce Committee in May. A full U.S House YES vote on this bill would prohibit “spread pricing” in Medicaid, establish a “pass-through payment” model and create a Medicaid managed care “rate floor” similar to that of Medicaid fee-for-service that focuses on cost-based pharmacy reimbursement and dispensing fees.
It is imperative to sustain momentum behind this crucial effort and advance PBM reform. NACDS RxIMPACT is calling on YOU, and all others, to AGAIN channel your efforts to tell the House to stand strong and confront ‘pharmaceutical benefit manipulation’ in the legislative process. We know PBMs will attack and complicate these straightforward and necessary reforms in misleading ways. Help us share the powerful REAL PBM REFORM ad message and remind Congress, if all patients don’t benefit from this package, it’s not REAL PBM REFORM.
Simply type in your contact information, click send message, and the system will generate a personalized communication to your Representative. If you have any questions or would like any assistance, please contact Heidi Ecker via telephone at 703-837-4121 or email.
Yesterday, the bipartisan membership of the House Energy and Commerce Committee approved three pieces of legislation including important PBM reforms: (1) H.R. 5393 to require CMS to establish pharmacy quality measures in Part D and that includes important PBM transparency provisions; (2) H.R. 5385 to create reporting requirements for PBMs under Medicare Part D; and (3) H.R. 2880 to prohibit PBMs participating in Medicare Part D from linking their service fees to a drug's list price.
EVEN FURTHER, we have learned a full U.S. House vote on an amended Lower Cost, More Transparency Act (H.R. 5378) could take place as soon as MONDAY! The bill is a conglomeration of important House Energy and Commerce Committee and House Ways and Means Committee PBM reform provisions, including the broader PATIENT Act that advanced through the Energy & Commerce Committee in May. A full U.S House YES vote on this bill would prohibit “spread pricing” in Medicaid, establish a “pass-through payment” model and create a Medicaid managed care “rate floor” similar to that of Medicaid fee-for-service that focuses on cost-based pharmacy reimbursement and dispensing fees.
It is imperative to sustain momentum behind this crucial effort and advance PBM reform. NACDS RxIMPACT is calling on YOU, and all others, to AGAIN channel your efforts to tell the House to stand strong and confront ‘pharmaceutical benefit manipulation’ in the legislative process. We know PBMs will attack and complicate these straightforward and necessary reforms in misleading ways. Help us share the powerful REAL PBM REFORM ad message and remind Congress, if all patients don’t benefit from this package, it’s not REAL PBM REFORM.
Simply type in your contact information, click send message, and the system will generate a personalized communication to your Representative. If you have any questions or would like any assistance, please contact Heidi Ecker via telephone at 703-837-4121 or email.
By providing your mobile number, you agree to receive periodic call to action text messages from National Association of Chain Drug Stores. Message and data rates may apply. Reply HELP for help. Reply STOP to unsubscribe. Message frequency varies.
Privacy Policy
*